Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (R,R)-Tramadol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 11/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 13/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 13/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 6/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 4/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (R,R)-Tramadol SCHEMBL14579837 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL7464 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL12831358 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL6543836 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL1593740 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL5318670 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL11984200 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL730723 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL57495 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| Tramadol SCHEMBL57496 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160039742-A1 | EXTRACTION OF TRAMADOL FROM NAUCLEA LATIFOLIA SMITH | UNIVERSITE JOSEPH FOURIER - GRENOBLE 1 (FR) | 2016-02-11 | — | — | US | disclosed |
| EP-2486921-A1 | Reducing Side Effects of Tramadol | DMI Biosciences, Inc. (US) | 2012-08-15 | — | — | EP | disclosed |
| EP-2486927-A1 | Treatment of Comorbid Premature Ejaculation and Erectile Dysfunction | DMI Biosciences, Inc. (US) | 2012-08-15 | — | — | EP | disclosed |
| EP-2120570-B1 | TREATMENT OF COMORBID PREMATURE EJACULATION AND ERECTILE DYSFUNCTION | DMI BIOSCIENCES INC (US) | 2012-05-16 | — | — | EP | disclosed |
| EP-2114147-B1 | REDUCING SIDE EFFECTS OF TRAMADOL | DMI BIOSCIENCES INC (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20120022071-A1 | Treatment of Comorbid Premature Ejaculation and Erectile Dysfunction | ROSEWIND CORPORATION | 2012-01-26 | — | — | US | disclosed |
| US-20120018345-A1 | Treatment of Comorbid Premature Ejaculation and Erectile Dysfunction | ROSEWIND CORPORATION | 2012-01-26 | — | — | US | disclosed |
| US-20120018333-A1 | Reducing Side Effects of Tramadol | ROSEWIND CORPORATION | 2012-01-26 | — | — | US | disclosed |
| WO-2010032254-A1 | INDUSTRIAL PROCESS FOR CIS(+M-2-R(DIMETHYLAMINO)-METHYL-1-(3- METHOXYPHENYL) CYCLOHEXANOL HYDROCHLORIDE | KAMUD DRUGS PVT . LTD . (IN) | 2010-03-25 | — | — | WO | disclosed |
| US-20090270248-A1 | Basic ionic liquids | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2009-10-29 | — | — | US | disclosed |
| WO-2008131256-A1 | IMPROVED TREATMENTS FOR PREMATURE EJACULATION IN HUMANS | TRINITY LABORATORIES INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080261991-A1 | comprising coadministering an effective amount of a phosphodiesterase inhibitor (PDE); reducing the incidence of newly-discovered side effects related to sexual function in human males | DMI BIOSCIENCES, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080262094-A1 | Treatment of Comorbid Premature Ejaculation and Erectile Dysfunction | DMI BIOSCIENCES, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| EP-1748978-A1 | CARBOXAMIDO OPIOID COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005113486-A1 | CARBOXAMIDO OPIOID COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-12-01 | — | — | WO | disclosed |
| EP-1346978-A1 | Process for preparing tramadol hydrochloride and/or tramadol monohydrate | Jubilant Organosys Limited (IN) | 2003-09-24 | — | — | EP | disclosed |
| EP-1313460-A2 | THERAPEUTIC USE AND FORMULATION OF (-)-TRAMADOL | Darwin Discovery Limited (GB) | 2003-05-28 | — | — | EP | disclosed |
| WO-2001034125-A2 | THERAPEUTIC USE AND FORMULATION OF (-)-TRAMADOL | DARWIN DISCOVERY LIMITED (GB) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039742-A1 | EXTRACTION OF TRAMADOL FROM NAUCLEA LATIFOLIA SMITH | OPRK1, OPRD1, OPRM1 | OPRM1 3/4885SLC6A2 15/4885SLC6A4 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.